These results indicate that glutathione plays a significant role in resistance to 3-BP in
yeast, either directly through interaction with 3-BP or indirectly. An amount of 2 mM BSO treatment resulted in a 45% lower GSH and 30% higher frequency of genomic DNA deletions during mouse development (Reliene and Schiestl 2006). As BSO in minimally cytotoxic doses has limited secondary effects both on yeast (this study) and mammalian cells one can conclude that 3-BP in combination with BSO might be useful in anticancer therapy.